- Global Pharma News & Resources

Nevada-Based Biopharmaceutical Company EUCYT Joins Race for Treatment of COVID-19

Investigation New Drug (IND) application accepted by U.S. Food and Drug Administration

LAS VEGAS - May 8, 2020 - (

​Could human cell generation (stem cell therapy) prove to be a promising option for treating coronavirus, (COVID-19)? That is what clinical scientists and doctors at the Nevada-based, biopharmaceutical company, EUCYT Laboratories are exploring.

EUCYT’s team of scientists and doctors have developed a stem cell-derived based drug, COVIXO. The company developed COVIXO from biologic drugs previously produced and used to treat inflammatory lung diseases such as Chronic Obstructive Pulmonary Disease (COPD).

How it Works

COVIXO would be administered to COVID-19 positive patients through a series of injections when they are in the midst of a cytokine storm (when the body starts to attack its own cells) with increased risk of inflammation or pneumonia and the need for ICU admittance/ventilation. EUCYT scientists believe COVIXO would assist with resolving inflammation, repairing epithelial damage, and strengthening the body’s ability to fight and eliminate the virus.

“Essentially, COVIXO would boost the individual’s own immune system. The hope is that the body will be able to fight off the disease by promoting the rapid generation of healthy immune cells,” said Tammy Luttrell Ph.D., EUCYT’s Chief Scientific Officer. “These stem cells are recovered from healthy donated tissue and serve as messengers between cells and also contain valuable information about the function of the body’s organs, including the lungs, where extreme inflammation and complications often occur as a result COVID-19 infection.” 

Additionally, as COVIXO is a stem-cell derived drug therapy, it may provide the opportunity to treat both infected and healthy patients sooner without the need for specific anti-viral therapies or vaccines—which could take years to develop and approve through the FDA, said Lutrell.

Next Steps, FDA Approved Phase I Clinical Trial

Joining the worldwide race for an effective treatment, EUCYT’s Investigation New Drug (IND) is pending approval. The company is working closely with the FDA and looks to start a Phase I Clinical Trial soon.

“People the world over are suffering and there is so much at stake right now—lives, the economy and the future of our global community as a whole,” said Travis H. Bird, founder and CEO of EUCYT. “As we seek FDA approval to conduct rigorous formal clinical trials, our goal is to simply get people what they need so that we can help combat this deadly disease. We are hopeful and encouraged that COVIXO is a potential treatment therapy that can be used to help ease the amount of devastation caused by COVID-19.”


EUCYT is a healthcare solutions company focused on harnessing the power of the human body to change the way we heal. EUCYT is committed to delivering the most effective and innovative products in generative therapy using over 45 years of research information. Our expansive product offerings come from live, healthy births and provide a superior approach to regenerative medicine. Located in the heart of Las Vegas, the lab has leveraged biotechnology innovations to collect, recover, and cryopreserve tissues with generative potential to harness cellular and tissue-based products to change the future of medical therapeutics. For more information, visit


EUCYT has manufactured COVIXO, cell signaling proteins and microRNA’s that strengthen the capacities of the immune system to respond to disease, whether viral or bacterial, or both. COVIXO has the potential to augment the natural cellular response against SARS-CoV-2. This enables each patient to generate their own adaptive immune response, including memory T cells and antibodies, which will further protect each patient from subsequent exposures and infections. COVIXO has a low immunogenicity, high biocompatibility, and the ability to overcome biological barriers allowing them to traverse throughout the entire body. COVIXO is non-toxic to host cells in your body.

For Media Inquiries email Denise Bird, Director of Marketing & Sponsorships 

Press Release Service by

Original Source: Nevada-Based Biopharmaceutical Company EUCYT Joins Race for Treatment of COVID-19

Editor Details

  • Company:
    • Newswire
Last Updated: 07-Jan-2021